Gene · 27036
Papers1,589
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,589
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Siglec-7 orchestrates mitochondrial dynamics and metabolic reprogramming to restrain human NK cell cytotoxic function. | J Biol Chem | 2026 | 42710663 | PubTator, text mining | PubMed |
| Loss of ST8SIA6 is associated with enhanced MUC16-Integrin β4 signaling and aggressive phenotypes in colorectal cancer. | Biochem Biophys Rep | 2026 | 42698897 | PubTator, text mining | PubMed |
| Persistent Cytotoxic Immune Signaling in Anti-VEGF-Treated Neovascular Age-Related Macular Degeneration. | medRxiv | 2026 | 42643214 | PubTator, text mining | PubMed |
| FOS regulation of T-cell activation and the mechanism of inflammatory injury of coronary endothelium in Kawasaki disease. | Transl Pediatr | 2026 | 42433922 | PubTator, text mining | PubMed |
| Nectin-4 as predictive biomarker of immune-related adverse event subtypes in adjuvant anti-programmed-death-1 treatment of melanoma. | Melanoma Res | 2026 | 42421561 | PubTator, text mining | PubMed |
| Prediction of Novel Disease-Related Regions in SIGLEC-7 by In Silico and Biochemical Analyses. | Int J Mol Sci | 2026 | 42353205 | PubTator, text mining | PubMed |
| Patient-derived organotypic tumor spheroids as a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma. | J Immunother Cancer | 2026 | 42082269 | PubTator, text mining | PubMed |
| Abnormal glycosylation of MUC20 mediates TAM polarization and promotes immune escape in colorectal cancer. | Commun Biol | 2026 | 41965932 | PubTator, text mining | PubMed |
| Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma. | Cancer Immunol Immunother | 2026 | 41961075 | PubTator, text mining | PubMed |
| Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity. | Science | 2026 | 41955354 | PubTator, text mining | PubMed |
| Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. | Oncoimmunology | 2026 | 41928453 | PubTator, text mining | PubMed |
| Siglec-7 inhibits TLR3-induced pro-inflammatory cytokine production from human monocytes and macrophages. | Front Immunol | 2026 | 41924269 | PubTator, text mining | PubMed |
| New Sialic Acid-Binding Site of SIGLEC-7. | Adv Exp Med Biol | 2026 | 41917391 | PubTator, text mining | PubMed |
| Defective HLA-G1 glycosylation disrupts Siglec-7-mediated NK cell tolerance at the maternal-fetal interface in recurrent pregnancy loss. | Cell Commun Signal | 2026 | 41882745 | PubTator, text mining | PubMed |
| Ex vivo and in vivo CRISPR/Cas9 screenings identify the roles of protein N-glycosylation in regulating T-cell activation and functions. | Elife | 2026 | 41860948 | PubTator, text mining | PubMed |
| A nanopore-based HIV-1 reference epitranscriptome. | Nucleic Acids Res | 2026 | 41854072 | PubTator, text mining | PubMed |
| Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. | Cell Rep Med | 2026 | 41850238 | PubTator, text mining | PubMed |
| Molecular mechanisms of tumor-associated macrophages in hepatocellular carcinoma development and therapy. | World J Gastroenterol | 2026 | 41809883 | PubTator, text mining | PubMed |
| SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immunosuppressive Microenvironment. | CNS Neurosci Ther | 2026 | 41795144 | PubTator, text mining | PubMed |
| The OX40/OX40L Axis Promotes Th2 Activity and Impairs Regulatory T Cell Function in Atopic Dermatitis. | Allergy | 2026 | 41793700 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/27036/papers